Aim: The primary aim of this study was to investigate whether ascorbic acid (AA) supplementation improves postprandial glucose responses under free-living conditions in individuals with type 2 diabetes. A secondary aim was to investigate the effect of AA supplementation on blood pressure. Conclusions: Individuals with type 2 diabetes experienced improved postprandial and 24-hour glycaemia and decreased BP after 4 months of AA supplementation as compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and BP control in individuals with type 2 diabetes.
| INTRODUCTION
Ascorbic acid (AA) is a major water-soluble antioxidant that decreases cellular and tissue oxidative stress. [1] [2] [3] Oxidative stress has been proposed as an important underlying causative agent in the pathogenesis of insulin resistance 4 and hyperglycaemia-induced diabetes complications. 5 Furthermore, some studies have shown that supplementation with AA can improve whole body insulin action in individuals with type 2 diabetes (T2D). 6, 7 We recently found that a 4-month period of of AA supplementation increases insulin-mediated peripheral glucose disposal and decreases skeletal muscle oxidative stress during hyperinsulinaemia in individuals with T2D. 8 Improvements in insulin sensitivity with AA supplementation may subsequently promote improvements in glycaemic control. Indeed, findings of some studies, 7, [9] [10] [11] [12] but not others, 13 support the efficacy of AA supplementation in improving glycaemic outcomes, including lowering of HbA1c and fasting glucose concentrations in individuals with T2D.
Reliance on general measures such as HbA1c to characterize glycaemic control may fail to account for daily glycaemic excursions that can lead to acute hypoglycaemic events or transient postprandial hyperglycaemia. 14 Use of continuous glucose monitors (CGMs) can overcome such limitations by allowing assessment of daily glucose excursions into hyperglycaemia and hypoglycaemia under free-living conditions. Assessment of postprandial glycaemia is of particular importance clinically, given that evidence from epidemiological and interventional studies implicate postprandial hyperglycaemia as an independent risk factor for cardiovascular disease and cardiovascular events in individuals with T2D. [15] [16] [17] Assessment of hypoglycaemia is also clinically important, as severe hypoglycaemia may result in symptoms such as stupor, unconsciousness or even death, and is considered a potential risk with therapies that improve mean glycaemic control. 18 Currently, there is a paucity of data investigating the effects of AA supplementation on postprandial glycaemia and daily excursions into hyper-and hypo-glycaemia during free-living conditions in individuals with T2D.
Control of cardio-metabolic disease risk factors, including high blood pressure, is important in the management of T2D. 19 Systematic reviews of randomized controlled trials have reported potential beneficial effects of AA supplementation on blood pressure (BP) in individuals with T2D. 20, 21 However, the number of studies is limited and, among these studies, further limitations include a lack of specificity for AA only and short durations of supplementation. 20, 22, 23 Thus, there is a need to further explore the efficacy of AA supplementation in individuals with T2D.
The main aims of this study were to investigate the effects of AA supplementation on postprandial glucose responses, and on the duration of the time spent in periods of hyper-and hypo-glycaemia using ambulant CGMs. We hypothesized that AA supplementation would attenuate the daily postprandial increase in blood glucose concentrations, thereby lowering the duration of the time spent in hyperglycaemia in individuals with T2D. An additional aim of this study was to investigate the effects of AA supplementation on blood pressure.
| MATERIALS AND METHODS

| Study design and participants
A double-blind, placebo-controlled cross-over study (#ACTRN12616000276459) was undertaken in individuals with T2D.
Recruitment was undertaken via local newspaper advertisements during the period 2016-2017. Of the individuals screened by phone or email, 43 underwent clinical screening to confirm study eligibility.
Among these individuals, 31 were enrolled ( Figure S1 and Table 1 ). Diabetes management (n)
• Metformin 19
• Janumet (sitagliptin + metformin) 5
• Sulfonylurea 6
• SGLT2 inhibitor 2
• Lifestyle only 5
Anti-hypertensive (n)
• ACE inhibitor 6
• AT receptor antagonist 5
• Beta blocker 1
• Calcium Channel blocker 1
• Diuretic 1
Other medications (n)
• Anti-hypercholesterolaemic 18
• Cardiovascular-related 5
• GERD/gout/anti-depressive/anti-10 
| Standardized diet
A standardized diet (Table S1 ) was provided to participants, to consume over the 48-hour period of CGM recording. Energy content of the diet was based on individual estimated requirements using the Schofield equation, 25 with an activity factor of 1.4 applied. The macronutrient profile of the daily diet, main meals (n = 3) and snacks (n = 2) was approximately 55% carbohydrate, 25% fat and 20% protein. 26, 27 The nutrient composition of the diet was established using
Foodworks software (v.9.0 Xyris, Australia). The same diet was maintained for participants during each 48-hour testing period.
| Outcome measures, sample size determination and compliance
The primary outcome of the study was postprandial glucose incremental area under the curve (iAUC) above basal glucose, assessed as a cumulative total (10.5 hours) of the 3.5-hour post-prandial periods after each main meal. 26 A sample size of n = 22 was determined to provide 95% power (α = 0.05, two-tailed t-test) to detect a 50% reduction in post-prandial glucose iAUC after 4 months of AA supplementation. 26 
| Analytical methods
Total plasma AA concentration was measured using an Ultimate 3000
Thermofisher HPLC system with UV detection as described previously. 28 Plasma insulin was measured using a human insulin ELISA (Alpco, Salem, New Hampshire) according to the manufacturer's instructions. Free F 2 -isoprostanes were measured in plasma samples using negative chemical ionization gas-chromatography-mass spectrometry (GC-MS) with an Agilent 7983 GC and Agilent 5975 MS according to prior methods, 29 with some modifications. F 2 -isoprostanes (8,12-iso-iPF2α-VI, 5-iPF2α-VI, 8-iso PGF2α) were measured and quantified using added deuterated internal standards (0.5 ng each of 8,12-iso-iPF2α-VI-d11, 5-iPF2α-VI-d11 and 8-iso PGF2α-d4). F 2 -isoprostanes were observed as two main chromatographic peaks, as shown previously. 29, 30 Peak 1 contained 5-iPF2α-VI and 8-iso-PGF2α, while peak 2 contained 8,12-iso-iPF2α-VI. Peak 1 concentration was quantified using 569 m/z, corrected for the combined responses of 8-iso-PGF2α-d4 (573 m/z) and 5-iPF2α-VI-d11 (580 m/z), while peak 2 concentration was quantified using 569 m/z corrected for 8,12-isoiPF2α-VI-d11 (580 m/z). The two peak concentrations were added together for total free F 2 -isoprostanes concentration.
| Compliance and adverse effects
Compliance was determined by capsule counts, using the equation:
number of capsules consumed/number of capsules expected to be consumed for full compliance ×100%. Participants completed a four-day diet record and a seven-day physical activity recall prior to commencement of each treatment 8 to monitor consistency of diet and physical activity. Participants were contacted monthly to follow-up on regular capsule ingestion, to inform them of any treatment changes, and to note any adverse effects to health that may have arisen subsequent to the supplementation.
| Statistics
AA and placebo trials were compared using ANCOVA (SPSS v.23;
IBM, Armonk, New York) with the within-subject difference in post-supplementation responses as the dependent variable and the corresponding difference in pre-supplementation responses as a covariate. 31 Adjusted mean differences between treatments and effect sizes (Cohen's d) were determined from ANCOVA data. Two-way repeated measures ANOVA with Fisher's LSD tests were used to assess withintreatment pre-post changes (Prism v.6.0; Graphpad Software Inc., La Jolla, California). Paired t-tests or Wilcoxon rank tests were used to compare survey measures of energy intake, vitamin C intake and physical activity energy expenditure 32 among treatments.
Both complete-case (CC) and per-protocol (PP) analyses were performed. Less than 5% of data were missing across randomized participants; therefore, we opted for CC rather than intention-totreat main analyses as little bias is expected. 33 PP analyses included data concerning all participants for whom data was complete, who remained consistent in treatment, and who were at least 80%
capsule compliant. To model the impact of missing data, sensitivity analyses of key outcomes were undertaken using "last-observation- were investigated using two-way ANOVA with treatment order as the between-subject factor. Significance was set at P < 0.05 for all analyses.
3 | RESULTS
| Participants
Among the 31 participants who were initially enrolled, 27 completed the study, and their data were used in the main analyses. Two participants withdrew from the study prior to treatment order randomiza- Table 2 ). Raw post-prandial glucose data are provided in Figure S1 .
| Duration of day spent with hyper-and hypoglycaemia
Duration of the day spent with hyperglycaemia significantly decreased (P = 0.03) during AA supplementation relative to an increased (P < 0.01) response during placebo administration (P < 0.01 between the two; adjusted mean change vs placebo, −2.8 h/d; Cohen's d = 1.15) (Figure 1 ). Duration of time within the 10.5-hour postprandial period with hyperglycaemia significantly decreased during AA supplementation (P = 0.04) relative to a significantly increased (P < 0.01) response during placebo administration (Table 2 ). There was no significant effect of AA supplementation on duration of the day spent with hypoglycaemia ( Table 2 ).
| Average 24-hour glucose and general glycaemic measures
Average 24-hour glucose decreased during AA supplementation relative to a significantly increased (P < 0.01) response during placebo administration (P < 0.05 between the two; adjusted mean change vs placebo, −0.8 mmol/L; Cohen's d = 0.83) (Figure 1 ). There were no significant differences between or within treatments for HbA1c, fasting glucose or insulin (Table 2 ).
| Blood pressure
Both SBP (P < 0.05) and DBP decreased during AA supplementation compared to placebo (P < 0.01 between the two) ( Figure 2 ). Adjusted 
| Body composition, lipids, energy expenditure and renal and liver function
There were no significant differences between or within treatments for measures of body composition, serum lipids and accelerometermeasured physical activity energy expenditure (Table 2) . AA supplementation had no effect on serum renal or liver function measures, including creatinine, urea, uric acid, bilirubin, albumin (data not shown), estimated glomerular filtration rate, alkaline phosphatase, gamma glutamyltransferase, aspartate aminotransferase and alanine aminotransferase ( Table 2) .
| Plasma AA concentration
AA concentration significantly increased (P < 0.01) during AA supplementation compared to placebo (P < 0.01 between treatments; adjusted mean change vs placebo, +50.0 μmol/L; Cohen's d = 4.23) (Figure 3 ).
| F 2 -Isoprostanes
Total free plasma F 2 -isoprostanes concentration (peak 1 + peak 2)
decreased significantly (P = 0.03) during AA supplementation, but was 
| PP analyses (n = 20)
Overwhelmingly, findings of the PP analyses were quantitatively and statistically similar to those of the main analyses (Tables S2 and S3 ).
An exception concerned fat free mass, which was found to decrease with placebo relative to AA supplementation (P < 0.05 for comparison between the two). However, the relatively small magnitude of difference between AA supplementation and placebo concerning fat-free mass (+0.6 kg) is unlikely to be of clinical significance.
| Sensitivity analyses
Sensitivity analyses that evaluated missing data using LOCF and MI confirmed the statistical significance of key outcome measures reported in the main analyses (Table S4) . Two-way ANOVA using presupplementation values and within-supplementation changes with treatment order as the between-subject factor revealed no effect of treatment order on any key outcome measure. This suggests an absence of carry-over effects of treatments. While we cannot confirm the mechanism(s) of post-prandial glucose improvement based on our data, we speculate, based on prior findings, that the improved response occurred via an increase in insulin-mediated peripheral glucose disposal. 8 In that study, AA supplementation also increased skeletal muscle AA concentrations and decreased muscle oxidative stress during hyperinsulinaemia, which is suggestive of an ameliorative antioxidant effect on muscle insulin sensitivity. 8 Paolisso et al. 7 reported decreased plasma-free radicals (O 2 ) along with improved insulin-mediated whole-body glucose disposal in elderly individuals with T2D who were undergoing an AA dosage regimen similar to that of our study. We observed a significant decrease in the concentration of plasma-free F 2 -isoprostanes during AA supplementation, which was largely the result of a decreased concentration of the plasma F 2 -isoprostanes fraction co-eluting with 8,12-iso-iPF2α-VI. There has been limited specific investigation of 8,12-iso-iPF2α-VI FIGURE 3 Effect of AA supplementation on plasma concentrations of ascorbic acid and F 2 -isoprostanes in main analyses (n = 27). A, plasma ascorbic acid concentration. B, total free F 2 -isoprostane concentration (peak 1 + peak 2). C, F 2 -isoprostane peak 1 concentration (containing 5-iPF2α-VI and 8-iso PGF2α) 4D shows F 2 -isoprostane peak 2 concentration (containing 8,12-iso-iPF2α-VI); *Denotes significant difference (P < 0.05) between points. Statistical analysis for peak 1 was made using log-transformed normalized data. Bars represent the mean (or geometric mean for peak 1). Open circles represent individual pre-supplementation data, while closed circles represent post supplementation data in individuals with T2D, although its concentration appears to be sensitive to oxidative stress 37, 38 and it is an F 2 -isoprostanes isomer that is relatively prevalent in human plasma. 39 Another potential limitation of our study is that our cohort was predominantly male. Thus, the number of females was not adequate to undertake a reliable gender subgroup analysis. Despite this, it was apparent that all female participants followed the same general pattern of improvement across key outcome measures as did the cohort on whole.
| DISCUSSION
Compliance in the present study was high and the number of reported adverse effects was low, suggesting that AA may be safely and consistently used in addition to a primary diabetes treatment.
Given the potential side effects with common anti-diabetic medications, such as hypoglycaemia and weight gain, the idea that a relatively benign and inexpensive vitamin supplement might play a role in managing diabetes has particular appeal. Thus, findings of the current study implicate AA supplementation as a potentially useful adjunct therapy in individuals with T2D for management of both glycaemia and blood pressure.
